XPHARMA
Board
1 director, last change in 2022Director (not named in the articles)
since 01-10-2016
term without a fixed end
earlier manager (not named in the articles), until 28-09-2022
listed in the 2025 annual accounts, filed on 24-03-2026
Mandates through the years
1 name, the dashed line is todayXavier Punie
Director (not named in the articles)
Director (not named in the articles)
BoardEarliermandate already running before its first mention
Mandates as a list
- Xavier Punie
- Director (not named in the articles), from 01-10-2016 to date
- Manager (not named in the articles), until 28-09-2022
Control
Shareholder
Lorenzo De Vlegelaer
share not stated
This company
XPHARMA
Equity €889,956
Profit €318,475 in 2025
Capital
- Contribution
- €18,600
- Source
- 2025 annual accounts
Articles of association
deed of 28-09-2022 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- “Register van aandelen op naam, aandeelhouders mogen kennis nemen betreffende hun effecten”
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Voor helft overdrager voor helft koper(s) naar evenredigheid aantal bij meer dan één koper, geen beroep op rechter tegen weigering”
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Third Thursday of February at 10:00
Shareholders
2 ownersOwners 2
- Lorenzo De Vlegelaernatural personSourceown accounts 31-08-2020share not stated
- Xavier Punienatural personSourceown accounts 31-08-2020share not stated